Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
Following the success of Egis Russia and Egis Polska, we are proud to announce that Egis Praha has also been recognized as Best Employer at Aon Hewitt’s Employee Engagement Survey.
Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.